|Day Low/High||5.93 / 6.00|
|52 Wk Low/High||3.07 / 13.80|
The VELOCITY Study Begins for Long-Acting Recombinant Human Growth Hormone in GHD Pediatric Patients
Conference Call and Webcast Scheduled at 8:30 a.m. ET on January 5, 2015
Conference Call and Webcast Scheduled for 4:30 p.m. ET on November 6, 2014
Versartis Strengthens Leadership Team to Prepare for Commercialization of VRS-317
Conference Call Will Include Third Quarter 2014 Financial Results and Business Update
Often when above-average volume moves into an equity, it precedes a large spike in volatility.
Biopharmaceutical company Versartis (VSAR) closed up 47.62% to $31 on Friday, its first day of trading after the company's initial public offering. The stock surged more than 50% to a high of $36.30 for the day. Nearly 6 million shares changed hands on Friday. Versartis upsized its IPO and earned $126 million by selling 6 million shares at $21 a share, the high end of its range of $19 to $21 a share. The company had previously expected to sell 4.6 million shares at $16 to $19 a share.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.